# SAVOIR (NCT03091192)

> Savolitinib vs. Sunitinib in MET-driven PRCC.

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03091192
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: AstraZeneca
- Conditions: Carcinoma; Carcinoma, Renal Cell; Kidney Neoplasms; Urologic Neoplasms; Kidney Diseases; Neoplasms by Site; Enzyme Inhibitors; Protein Kinase Inhibitors
- Interventions: Savolitinib; Sunitinib
- Enrollment: 60
- Primary outcome: Progression Free Survival (PFS) by Blinded Independent Central Review (BICR)

## Indexed commentary on SAVOIR so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 12
- YouTube: 6
- Podcasts: 3

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=savoir-nct03091192

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03091192", "email": "<work email>"}; the inbox owner confirms by the emailed link.